A large international study called the REBOOT trial has found that beta blockers, a common treatment for heart attack survivors with normal heart function, do not provide benefits and may increase risks for women, challenging decades of standard practice.
A large international study called REBOOT found that beta-blockers may not provide benefits for most heart attack patients with preserved heart function, and could even be harmful to women, suggesting a need to revise current treatment guidelines.
The REBOOT trial found that beta blockers, a standard treatment for heart attack patients for over 40 years, provide no benefit for those with uncomplicated myocardial infarction and may be risky for women, potentially leading to a change in global clinical guidelines.
The REBOOT trial found that beta blockers, a standard treatment for heart attack patients with preserved heart function, offer no significant benefit and may increase risks for women, potentially leading to a change in clinical guidelines worldwide.